title: A case of eczematous and vesicular dermatitis during anti-TNFalpha therapy for rheumatoid arthritis.
authors.forename: F
authors.initials: F
authors.lastname: Savoia
authors.forename: G
authors.initials: G
authors.lastname: Gaddoni
authors.forename: C
authors.initials: C
authors.lastname: Casadio
authors.forename: G
authors.initials: G
authors.lastname: Spadola
authors.forename: A
authors.initials: A
authors.lastname: Patrizi
authors.forename: F
authors.initials: F
authors.lastname: Giacomini
authors.forename: M
authors.initials: M
authors.lastname: Aldi
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003951:Diagnostic Errors; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004485:Eczema / Q000139:chemically induced* / Q000175:diagnosis; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077339:Leflunomide; D011537:Pruritus / Q000139:chemically induced; D011565:Psoriasis / Q000175:diagnosis; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000037:antagonists & inhibitors*; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000175:diagnosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; C415902:TNFRSF1B protein, human; D014409:Tumor Necrosis Factor-alpha; D000077339:Leflunomide; D000068800:Etanercept